Skip To Main Content
Karmugi Balaratnam on Muck Rack

Karmugi Balaratnam

As seen in: The BMJ, medRxiv, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Karmugi

Contact Karmugi, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events

|
By Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Karmugi Balaratnam
| The BMJ Verified
Clinical cancer immunotherapy Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Open in Who Shared Issue with article?

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events

|
By Pooja Middha, Rohit Thummalapalli, Zoe Quandt, Karmugi Balaratnam
| medRxiv
The authors have declared no competing interest.
Open in Who Shared View Duplicates (105) Issue with article?
See all 2 articles